FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 345:1515-1521 November 22, 2001 Number 21 Next

	Full Text PDF Editorial by Breitner, J. C.S. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Previous studies have suggested that the use of nonsteroidal antiinflammatory drugs (NSAIDs) may help to prevent Alzheimer's disease. The results, however, have been inconsistent.

Methods We studied the association between the use of NSAIDs and Alzheimer's disease and vascular dementia in a prospective, population-based cohort study of 6989 subjects 55 years of age or older who were free of dementia at base line. The risk of Alzheimer's disease was estimated in relation to the use of NSAIDs as documented in pharmacy records. We defined four mutually exclusive categories of use: nonuse, short-term use (1 month or less of cumulative use), intermediate-term use (more than 1 but less than 24 months of cumulative use), and long-term use (24 months or more of cumulative use). Adjustments were made by Cox regression analysis for age, sex, education, smoking status, and the use or nonuse of salicylates, histamine H₂-receptor antagonists, antihypertensive agents, and hypoglycemic agents.

Results During an average follow-up period of 6.8 years, dementia developed in 394 subjects, of whom 293 had Alzheimer's disease, 56 vascular dementia, and 45 other types of dementia. The relative risk of Alzheimer's disease was 0.95 (95 percent confidence interval, 0.70 to 1.29) in subjects with short-term use of NSAIDs, 0.83 (95 percent confidence interval, 0.62 to 1.11) in those with intermediate-term use, and 0.20 (95 percent confidence interval, 0.05 to 0.83) in those with long-term use. The risk did not vary according to age. The use of NSAIDs was not associated with a reduction in the risk of vascular dementia.

Conclusions The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia.

Source Information

From the Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands (B.A.V., A.R., A.H., C.M.D., T.S., M.M.B.B., B.H.C.S.); the Epidemiology, Demography, and Biometry Program, National Institute on Aging, National Institutes of Health, Bethesda, Md. (L.J.L.); and the Inspectorate for Health Care, The Hague, the Netherlands (B.A.V., B.H.C.S.).

Address reprint requests to Dr. Stricker at the Department of Epidemiology and Biostatistics, Erasmus Medical Center, P.O. Box 1738, 3000 DR Rotterdam, the Netherlands.

Full Text of this Article

This article has been cited by other articles:

• ADAPT Research Group, (2008). Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib. Arch Neurol 65: 896-905 [Abstract] [Full Text]  
• Szekely, C. A., Green, R. C., Breitner, J.C.S., Ostbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., Psaty, B. M., Resnick, S. M., Wolf, P. A., Zonderman, A. B., Welsh-Bohmer, K. A., Zandi, P. P. (2008). No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70: 2291-2298 [Abstract] [Full Text]  
• Arvanitakis, Z., Grodstein, F., Bienias, J. L., Schneider, J. A., Wilson, R. S., Kelly, J. F., Evans, D. A., Bennett, D. A. (2008). Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70: 2219-2225 [Abstract] [Full Text]  
• Vlad, S. C., Miller, D. R., Kowall, N. W., Felson, D. T. (2008). Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70: 1672-1677 [Abstract] [Full Text]  
• Choi, S.-H., Langenbach, R., Bosetti, F. (2008). Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J. 22: 1491-1501 [Abstract] [Full Text]  
• Kotilinek, L. A., Westerman, M. A., Wang, Q., Panizzon, K., Lim, G. P., Simonyi, A., Lesne, S., Falinska, A., Younkin, L. H., Younkin, S. G., Rowan, M., Cleary, J., Wallis, R. A., Sun, G. Y., Cole, G., Frautschy, S., Anwyl, R., Ashe, K. H. (2008). Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity. Brain 131: 651-664 [Abstract] [Full Text]  
• Szekely, C. A., Breitner, J.C.S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., Zandi, P. P. (2008). NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type. Neurology 70: 17-24 [Abstract] [Full Text]  
• Hoshino, T., Nakaya, T., Homan, T., Tanaka, K.-i., Sugimoto, Y., Araki, W., Narita, M., Narumiya, S., Suzuki, T., Mizushima, T. (2007). Involvement of Prostaglandin E2 in Production of Amyloid-beta Peptides Both in Vitro and in Vivo. J. Biol. Chem. 282: 32676-32688 [Abstract] [Full Text]  
• LICASTRO, F., CHIAPELLI, M., CALDARERA, C. M., CARUSO, C., LIO, D., CORDER, E. H. (2007). Acute Myocardial Infarction and Proinflammatory Gene Variants. Ann. N. Y. Acad. Sci. 1119: 227-242 [Abstract] [Full Text]  
• Bowler, J. V. (2007). Modern concept of vascular cognitive impairment. Br Med Bull 83: 291-305 [Abstract] [Full Text]  
• Zou, K., Yamaguchi, H., Akatsu, H., Sakamoto, T., Ko, M., Mizoguchi, K., Gong, J.-S., Yu, W., Yamamoto, T., Kosaka, K., Yanagisawa, K., Michikawa, M. (2007). Angiotensin-Converting Enzyme Converts Amyloid {beta}-Protein 1 42 (A{beta}1 42) to A{beta}1 40, and Its Inhibition Enhances Brain A{beta} Deposition. J. Neurosci. 27: 8628-8635 [Abstract] [Full Text]  
• Tenenbaum, M., Azab, A. N., Kaplanski, J. (2007). Effects of estrogen against LPS-induced inflammation and toxicity in primary rat glial and neuronal cultures. Innate Immunity 13: 158-166 [Abstract]  
• Prettyman, R. J (2007). Too little, too late?. BMJ 334: 1071-1071 [Full Text]  
• ADAPT Research Group, (2007). Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68: 1800-1808 [Abstract] [Full Text]  
• (2007). References. APPI Online CME 2007: 2-2 [Full Text]  
• Dahan, A., Hoffman, A. (2007). Mode of Administration-Dependent Brain Uptake of Indomethacin: Sustained Systemic Input Increases Brain Influx. Drug Metab. Dispos. 35: 321-324 [Abstract] [Full Text]  
• Green, R. C., DeKosky, S. T. (2006). Primary prevention trials in Alzheimer disease.. Neurology 67: S2-S5 [Abstract] [Full Text]  
• POZZI, S., BENEDUSI, V., MAGGI, A., VEGETO, E. (2006). Estrogen Action in Neuroprotection and Brain Inflammation. Ann. N. Y. Acad. Sci. 1089: 302-323 [Abstract] [Full Text]  
• CANDORE, G., BALISTRERI, C. R, GRIMALDI, M. P, VASTO, S., LISTI, F., CHIAPPELLI, M., LICASTRO, F., LIO, D., CARUSO, C. (2006). Age-Related Inflammatory Diseases: Role of Genetics and Gender in the Pathophysiology of Alzheimer's Disease. Ann. N. Y. Acad. Sci. 1089: 472-486 [Abstract] [Full Text]  
• Murnaghan, M., Li, G., Marsh, D. R. (2006). Nonsteroidal Anti-Inflammatory Drug-Induced Fracture Nonunion: An Inhibition of Angiogenesis?. JBJS 88: 140-147 [Abstract] [Full Text]  
• Sang, N., Chen, C. (2006). Lipid Signaling and Synaptic Plasticity. Neuroscientist 12: 425-434 [Abstract]  
• Freund-Levi, Y., Eriksdotter-Jonhagen, M., Cederholm, T., Basun, H., Faxen-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., Palmblad, J. (2006). {omega}-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study: A Randomized Double-blind Trial.. Arch Neurol 63: 1402-1408 [Abstract] [Full Text]  
• Dvir, E., Friedman, J. E., Lee, J. Y., Koh, J. Y., Younis, F., Raz, S., Shapiro, I., Hoffman, A., Dahan, A., Rosenberg, G., Angel, I., Kozak, A., Duvdevani, R. (2006). A Novel Phospholipid Derivative of Indomethacin, DP-155 [Mixture of 1-Steroyl and 1-Palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl Choline], Shows Superior Safety and Similar Efficacy in Reducing Brain Amyloid beta in an Alzheimer's Disease Model. J. Pharmacol. Exp. Ther. 318: 1248-1256 [Abstract] [Full Text]  
• Rentzos, M., Zoga, M., Paraskevas, G. P., Kapaki, E., Rombos, A., Nikolaou, C., Tsoutsou, A., Vassilopoulos, D. (2006). IL-15 Is Elevated in Cerebrospinal Fluid of Patients With Alzheimer's Disease and Frontotemporal Dementia.. J Geriatr Psychiatry Neurol 19: 114-117 [Abstract]  
• Schapira, A. H.V. (2006). Etiology of Parkinson's disease. Neurology 66: S10-S23 [Abstract] [Full Text]  
• Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., Walter, J., Klockgether, T., van Leuven, F., Heneka, M. T. (2006). Nonsteroidal anti-inflammatory drugs repress {beta}-secretase gene promoter activity by the activation of PPAR{gamma}. Proc. Natl. Acad. Sci. USA 103: 443-448 [Abstract] [Full Text]  
• Masse, I, Bordet, R, Deplanque, D, Al Khedr, A, Richard, F, Libersa, C, Pasquier, F (2005). Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 76: 1624-1629 [Abstract] [Full Text]  
• van Oijen, M., Witteman, J. C., Hofman, A., Koudstaal, P. J., Breteler, M. M.B. (2005). Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia. Stroke 36: 2637-2641 [Abstract] [Full Text]  
• Liang, X., Wang, Q., Hand, T., Wu, L., Breyer, R. M., Montine, T. J., Andreasson, K. (2005). Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease. J. Neurosci. 25: 10180-10187 [Abstract] [Full Text]  
• Townsend, K. P., Pratico, D. (2005). Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 19: 1592-1601 [Abstract] [Full Text]  
• Westerheide, S. D., Morimoto, R. I. (2005). Heat Shock Response Modulators as Therapeutic Tools for Diseases of Protein Conformation. J. Biol. Chem. 280: 33097-33100 [Abstract] [Full Text]  
• Koenigsknecht-Talboo, J., Landreth, G. E. (2005). Microglial Phagocytosis Induced by Fibrillar {beta}-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines. J. Neurosci. 25: 8240-8249 [Abstract] [Full Text]  
• Schutz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G. E., Schurmann, B., Zimmer, A., Heneka, M. T. (2005). The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice. J. Neurosci. 25: 7805-7812 [Abstract] [Full Text]  
• Nelson, M. R, Liew, D., Bertram, M., Vos, T. (2005). Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged >=70. BMJ 330: 1306- [Abstract] [Full Text]  
• Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., Landreth, G. E. (2005). Acute treatment with the PPAR{gamma} agonist pioglitazone and ibuprofen reduces glial inflammation and A{beta}1-42 levels in APPV717I transgenic mice. Brain 128: 1442-1453 [Abstract] [Full Text]  
• Purandare, N., Ballard, C., Burns, A. (2005). Preventing dementia. Adv. Psychiatr. Treat. 11: 176-183 [Abstract] [Full Text]  
• Montine, T. J., Morrow, J. D. (2005). Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease. Am. J. Pathol. 166: 1283-1289 [Abstract] [Full Text]  
• Gorelick, P. B. (2005). William M. Feinberg Lecture: Cognitive Vitality and the Role of Stroke and Cardiovascular Disease Risk Factors. Stroke 36: 875-879 [Abstract] [Full Text]  
• Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., Cole, G. M. (2005). Curcumin Inhibits Formation of Amyloid {beta} Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo. J. Biol. Chem. 280: 5892-5901 [Abstract] [Full Text]  
• de Craen, A. J. M., Gussekloo, J., Vrijsen, B., Westendorp, R. G. J. (2005). Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia. Am J Epidemiol 161: 114-120 [Abstract] [Full Text]  
• COLE, G. M., MORIHARA, T., LIM, G. P., YANG, F., BEGUM, A., FRAUTSCHY, S. A. (2004). NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models. Ann. N. Y. Acad. Sci. 1035: 68-84 [Abstract] [Full Text]  
• KITAZAWA, M., YAMASAKI, T. R., LAFERLA, F. M. (2004). Microglia as a Potential Bridge between the Amyloid {beta}-Peptide and Tau. Ann. N. Y. Acad. Sci. 1035: 85-103 [Abstract] [Full Text]  
• Rentzos, M., Michalopoulou, M., Nikolaou, C., Cambouri, C., Rombos, A., Dimitrakopoulos, A., Kapaki, E., Vassilopoulos, D. (2004). Serum Levels of Soluble Intercellular Adhesion Molecule-1 and Soluble Endothelial Leukocyte Adhesion Molecule-1 in Alzheimer's Disease. J Geriatr Psychiatry Neurol 17: 225-231 [Abstract]  
• Pinder, R. M., Sandler, M. (2004). Alcohol, wine and mental health: focus on dementia and stroke. J Psychopharmacol 18: 449-456 [Abstract]  
• McGEER, P. L., McGEER, E. G. (2004). Inflammation and the Degenerative Diseases of Aging. Ann. N. Y. Acad. Sci. 1035: 104-116 [Abstract] [Full Text]  
• Camacho, I. E., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D., De Strooper, B. (2004). Peroxisome Proliferator-Activated Receptor {gamma} Induces a Clearance Mechanism for the Amyloid-{beta} Peptide. J. Neurosci. 24: 10908-10917 [Abstract] [Full Text]  
• Gorelick, P. B. (2004). Risk Factors for Vascular Dementia and Alzheimer Disease. Stroke 35: 2620-2622 [Abstract] [Full Text]  
• Chiang, N., Bermudez, E. A., Ridker, P. M., Hurwitz, S., Serhan, C. N. (2004). Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101: 15178-15183 [Abstract] [Full Text]  
• Selkoe, D. J. (2004). Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies. ANN INTERN MED 140: 627-638 [Full Text]  
• Nagano, S., Huang, X., Moir, R. D., Payton, S. M., Tanzi, R. E., Bush, A. I. (2004). Peroxidase Activity of Cyclooxygenase-2 (COX-2) Cross-links {beta}-Amyloid (A{beta}) and Generates A{beta}-COX-2 Hetero-oligomers That Are Increased in Alzheimer's Disease. J. Biol. Chem. 279: 14673-14678 [Abstract] [Full Text]  
• Gan, L., Ye, S., Chu, A., Anton, K., Yi, S., Vincent, V. A., von Schack, D., Chin, D., Murray, J., Lohr, S., Patthy, L., Gonzalez-Zulueta, M., Nikolich, K., Urfer, R. (2004). Identification of Cathepsin B as a Mediator of Neuronal Death Induced by A{beta}-activated Microglial Cells Using a Functional Genomics Approach. J. Biol. Chem. 279: 5565-5572 [Abstract] [Full Text]  
• Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B. A., Baranak, C. C. (2004). Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66-71 [Abstract] [Full Text]  
• Norfray, J. F., Provenzale, J. M. (2004). Alzheimer's Disease: Neuropathologic Findings and Recent Advances in Imaging. Am. J. Roentgenol. 182: 3-13 [Full Text]  
• Qin, W., Ho, L., Pompl, P. N., Peng, Y., Zhao, Z., Xiang, Z., Robakis, N. K., Shioi, J., Suh, J., Pasinetti, G. M. (2003). Cyclooxygenase (COX)-2 and COX-1 Potentiate {beta}-Amyloid Peptide Generation through Mechanisms That Involve {gamma}-Secretase Activity. J. Biol. Chem. 278: 50970-50977 [Abstract] [Full Text]  
• Monje, M. L., Toda, H., Palmer, T. D. (2003). Inflammatory Blockade Restores Adult Hippocampal Neurogenesis. Science 302: 1760-1765 [Abstract] [Full Text]  
• Benito, C., Nunez, E., Tolon, R. M., Carrier, E. J., Rabano, A., Hillard, C. J., Romero, J. (2003). Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains. J. Neurosci. 23: 11136-11141 [Abstract] [Full Text]  
• Sastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., van Leuven, F., Heneka, M. T. (2003). Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-{gamma} Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of {beta}-Secretase. J. Neurosci. 23: 9796-9804 [Abstract] [Full Text]  
• Helmuth, L. (2003). Detangling Alzheimer's Disease. Sci Aging Knowl Environ 2003: oa2-2 [Abstract] [Full Text]  
• Rosenthal, T. C., Khotianov, N. (2003). Managing Alzheimer Dementia Tomorrow. J Am Board Fam Med 16: 423-434 [Abstract] [Full Text]  
• Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V., Fauq, A., Golde, Todd. E., Koo, E. H. (2003). Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid {beta}42 Production by Direct Modulation of {gamma}-Secretase Activity. J. Biol. Chem. 278: 31831-31837 [Abstract] [Full Text]  
• Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., Landreth, G. (2003). Anti-Inflammatory Drug Therapy Alters {beta}-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease. J. Neurosci. 23: 7504-7509 [Abstract] [Full Text]  
• Martyn, C. (2003). Anti-inflammatory drugs and Alzheimer's disease. BMJ 327: 353-354 [Full Text]  
• Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Golde, Todd. E., Koo, E. H. (2003). A{beta}42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain. J. Biol. Chem. 278: 30748-30754 [Abstract] [Full Text]  
• Schiess, M. (2003). Nonsteroidal Anti-inflammatory Drugs Protect Against Parkinson Neurodegeneration: Can an NSAID a Day Keep Parkinson Disease Away?. Arch Neurol 60: 1043-1044 [Full Text]  
• Chen, H., Zhang, S. M., Hernan, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., Ascherio, A. (2003). Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease. Arch Neurol 60: 1059-1064 [Abstract] [Full Text]  
• Etminan, M., Gill, S., Samii, A. (2003). Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327: 128- [Abstract] [Full Text]  
• Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J. (2003). Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial. JAMA 289: 2819-2826 [Abstract] [Full Text]  
• Launer, L. J. (2003). Nonsteroidal Anti-inflammatory Drugs and Alzheimer Disease: What's Next?. JAMA 289: 2865-2867 [Full Text]  
• Holmes, C, El-Okl, M, Williams, A L, Cunningham, C, Wilcockson, D, Perry, V H (2003). Systemic infection, interleukin 1{beta}, and cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74: 788-789 [Abstract] [Full Text]  
• Gajraj, N. M. (2003). Cyclooxygenase-2 Inhibitors. Anesth. Analg. 96: 1720-1738 [Full Text]  
• Takahashi, Y., Hayashi, I., Tominari, Y., Rikimaru, K., Morohashi, Y., Kan, T., Natsugari, H., Fukuyama, T., Tomita, T., Iwatsubo, T. (2003). Sulindac Sulfide Is a Noncompetitive gamma -Secretase Inhibitor That Preferentially Reduces Abeta 42 Generation. J. Biol. Chem. 278: 18664-18670 [Abstract] [Full Text]  
• Landi, F., Cesari, M., Onder, G., Russo, A., Torre, S., Bernabei, R. (2003). Non-Steroidal Anti-Inflammatory Drug (NSAID) Use and Alzheimer Disease in Community-Dwelling Elderly Patients. AJGP 11: 179-185 [Abstract] [Full Text]  
• van Leeuwen, R, Vingerling, J R, Hofman, A, de Jong, P T V M, Stricker, B H C. (2003). Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 326: 255-256 [Full Text]  
• Neugroschl, J., Davis, K. L. (2002). Biological Markers in Alzheimer Disease. AJGP 10: 660-677 [Abstract] [Full Text]  
• in 't Veld, B. A., Launer, L. J., Breteler, M. M. B., Hofman, A., Stricker, B. H. Ch. (2002). Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence. Epidemiol Rev 24: 248-268 [Full Text]  
• Varner, A. E., Brenner, S., Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Aggarwal, N., Wilson, R. S., Scherr, P. A., Engelhart, M. J., Breteler, M. M. B. (2002). Antioxidants and Risk of Alzheimer Disease. JAMA 288: 2265-2266 [Full Text]  
• Zandi, P. P., Carlson, M. C., Plassman, B. L., Welsh-Bohmer, K. A., Mayer, L. S., Steffens, D. C., Breitner, J. C. S., for the Cache County Memory Study Investigators, (2002). Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women: The Cache County Study. JAMA 288: 2123-2129 [Abstract] [Full Text]  
• Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L., Breitner, J. C.S. (2002). Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 59: 880-886 [Abstract] [Full Text]  
• Lovestone, S (2002). Can we afford to develop treatments for dementia?. J. Neurol. Neurosurg. Psychiatry 72: 685-685 [Full Text]  
• Sood, A., Mounier, N., Andre, M., Lepage, E., Hull, M., Lieb, K., Fiebich, B. L., Press, D., Stricker, B. H.C., Hofman, A., Breteler, M. M.B. (2002). Nonsteroidal Drugs and Alzheimer's Disease. NEJM 346: 1171-1173 [Full Text]  
• (2002). A Boost for NSAIDs in Alzheimer's Prevention. JWatch Neurology 2002: 1-1 [Full Text]  
• Trojanowski, J. Q. (2002). Neuropathological Verisimilitude in Animal Models of Alzheimer's Disease : Key to Elucidating Neurodegenerative Pathways and Identifying New Targets for Drug Discovery. Am. J. Pathol. 160: 409-411 [Full Text]  
• (2002). NSAID Use and Risk for Alzheimer's Disease. JWatch Psychiatry 2002: 9-9 [Full Text]  
• (2001). NSAID Use and Risk for Alzheimer's Disease. JWatch General 2001: 2-2 [Full Text]  
• Breitner, J. C.S., Zandi, P. P. (2001). Do Nonsteroidal Antiinflammatory Drugs Reduce the Risk of Alzheimer's Disease?. NEJM 345: 1567-1568 [Full Text]